Somerville, United States
bluebird bio, founded in 1993, is pioneering in the realm of biotechnology with its ambitious pursuit of curative gene therapies aimed at providing patients and their families with more "bluebird days." The company centers on severe genetic disorders, presenting leading programs for conditions like sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
Headquartered in the United States, bluebird bio is renowned for possessing the largest and most comprehensive ex-vivo gene therapy data set worldwide. The organization custom designs its therapies to tackle the root causes of diseases, leveraging advanced lentiviral vector technologies.
In its most recent financial move, bluebird bio secured a $75.00M Post-IPO Debt investment on March 18, 2024, with Hercules Capital as an investor. This influx of capital underlines confidence in bluebird's vision and paves the way for continued innovation and expansion in biotechnology, health care, and pharmaceuticals.
